Physician profile
Mercy B Moore
NPI 1114927399
$210.63
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.19 | 2019 | |
| Insulet Corporation | $25.17 | 2019 | |
| Lilly USA, LLC | $19.17 | 2019 | |
| Amgen INC. | $18.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.89 | 2019 | |
| Antares Pharma, INC. | $14.67 | 2019 | |
| Abbvie INC. | $13.36 | 2019 | |
| Dexcom, INC. | $13.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.78 | 2019 | |
| Shire North American Group INC | $12.19 | 2019 | |
| Lifescan, INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercy Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.